Trastuzumab deruxtecan versus trastuzumab emtansine in Asian patients with HER2-positive metastatic breast cancer.

Autor: Iwata H; Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan., Xu B; Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China., Kim SB; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea., Chung WP; Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan., Park YH; Samsung Medical Center, Seoul, Korea., Kim MH; Severance Hospital, Yonsei University College of Medicine, Seoul, Korea., Tseng LM; Taipei Veterans General Hospital, Taipei, Taiwan., Chung CF; Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan., Huang CS; National Taiwan University Hospital, Taipei, Taiwan., Kim JH; Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seoul, Korea., Chiu JWY; Queen Mary Hospital, Hong Kong, China., Yamashita T; Kanagawa Cancer Center, Yokohama, Kanagawa, Japan., Li W; The First Hospital of Jilin University, Jilin, China., Egorov A; Daiichi Sankyo Inc., Basking Ridge, New Jersey, USA., Nishijima S; Daiichi Sankyo, Co., Ltd., Tokyo, Japan., Nakatani S; Daiichi Sankyo, Co., Ltd., Tokyo, Japan., Nishiyama Y; Daiichi Sankyo, Co., Ltd., Tokyo, Japan., Sugihara M; Daiichi Sankyo, Co., Ltd., Tokyo, Japan., Cortés J; International Breast Cancer Center, Quironsalud Group, Barcelona, Spain.; Medical Scientia Innovation Research, Barcelona, Spain.; Faculty of Biomedical and Health Sciences, Department of Medicine, Universidad Europea de Madrid, Madrid, Spain., Im SA; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.
Jazyk: angličtina
Zdroj: Cancer science [Cancer Sci] 2024 Sep; Vol. 115 (9), pp. 3079-3088. Date of Electronic Publication: 2024 Jul 09.
DOI: 10.1111/cas.16234
Abstrakt: The global phase 3 DESTINY-Breast03 study (ClinicalTrials.gov; NCT03529110) showed statistically significant and clinically meaningful improvements in progression-free survival (PFS) and overall survival (OS) with trastuzumab deruxtecan (T-DXd) over trastuzumab emtansine (T-DM1) in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (mBC) previously treated with trastuzumab and a taxane. Here, we report a subgroup analysis of Asian patients enrolled in DESTINY-Breast03. In total, 309 patients (149 in the T-DXd arm and 160 in the T-DM1 arm) from Asian countries and regions were randomized. At data cutoff (July 25, 2022), the median duration of follow-up in the Asian subpopulation was 29.0 months with T-DXd and 26.0 months with T-DM1. The PFS (determined by blinded independent central review) hazard ratio was 0.30 (95% confidence interval 0.22-0.41) favoring T-DXd over T-DM1 (median PFS 25.1 vs. 5.4 months). Median OS was not reached in the T-DXd arm and was 37.7 months in the T-DM1 arm. The median treatment duration was 15.4 months with T-DXd and 5.5 months with T-DM1. The incidence of grade ≥3 drug-related treatment-emergent adverse events was similar between both treatment arms (49.0% vs. 46.5%) and was consistent with the overall DESTINY-Breast03 population. Adjudicated drug-related interstitial lung disease or pneumonitis occurred in 12.9% of patients treated with T-DXd and 2.5% treated with T-DM1, with a higher incidence in Japanese patients; none of these were grade ≥4 events. These efficacy and safety data reinforce the favorable benefit-risk profile of T-DXd in HER2-positive mBC, including in the Asian subgroup.
(© 2024 The Author(s). Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.)
Databáze: MEDLINE
Externí odkaz: